Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 4/20 | 0.32 |
| ▸ | CA1 | P00915 | 4/20 | 0.32 |
| ▸ | CA2 | P00918 | 4/20 | 0.32 |
| ▸ | CA4 | P22748 | 4/20 | 0.32 |
| ▸ | CA9 | Q16790 | 4/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GLP1R | P43220 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18886281 | 0.84 | CRBN (0.41) | CRBNMEN1KMT2ACA12CA1 | |
| SCHEMBL17282361 | 0.84 | CRBN (0.41) | CRBNMEN1KMT2ACA12CA1 | |
| SCHEMBL14139642 | 0.84 | CRBN (0.35) | CRBN | |
| SCHEMBL30980666 | 0.84 | CRBN (0.37) | CRBNMEN1KMT2ACA12CA1 | |
| SCHEMBL13228187 | 0.82 | TSHR (0.44) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL13228134 | 0.81 | CA2 (0.36) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL14139797 | 0.81 | MEN1 (0.39) | MEN1KMT2AALDH1A1SMN1; SMN2GLP1R | |
| SCHEMBL26133569 | 0.81 | NOS3 (0.41) | CRBNKMT2ACA12CA1CA2 | |
| SCHEMBL31297097 | 0.81 | MEN1 (0.38) | CRBNMEN1KMT2ACA12CA1 | |
| SCHEMBL26133563 | 0.81 | NOS3 (0.41) | CRBNKMT2ACA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722018-B2 | Method for preparing nanoparticles covered with a gem-bisphosphonate stabilizing layer coupled to hydrophilic distribution ligands | GUERBET (FR) | 2014-05-13 | — | — | US | disclosed |
| US-8722018-B2 | Method for preparing nanoparticles covered with a gem-bisphosphonate stabilizing layer coupled to hydrophilic distribution ligands | GUERBET (FR) | 2014-05-13 | — | — | US | disclosed |
| EP-2205284-B1 | NOVEL METHOD FOR PREPARING NANOPARTICLES COVERED WITH A GEM-BISPHOSPHONATE STABILISING LAYER COUPLED TO HYDROPHILIC BIODISTRIBUTION LIGANDS | GUERBET SA (FR) | 2012-12-05 | — | — | EP | disclosed |
| US-20100215586-A1 | NOVEL METHOD FOR PREPARING NANOPARTICLES COVERED WITH A GEM-BISPHOSPHONATE STABILIZING LAYER COUPLED TO HYDROPHILIC BIODISTRIBUTION LIGANDS | GUERBET (FR) | 2010-08-26 | — | — | US | disclosed |
| US-20100215586-A1 | NOVEL METHOD FOR PREPARING NANOPARTICLES COVERED WITH A GEM-BISPHOSPHONATE STABILIZING LAYER COUPLED TO HYDROPHILIC BIODISTRIBUTION LIGANDS | GUERBET (FR) | 2010-08-26 | — | — | US | disclosed |
| WO-2009053596-A2 | NOVEL METHOD FOR PREPARING NANOPARTICLES COVERED WITH A GEM-BISPHOSPHONATE STABILISING LAYER COUPLED TO HYDROPHILIC BIODISTRIBUTION LIGANDS | GUERBET (FR) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100215586-A1 | NOVEL METHOD FOR PREPARING NANOPARTICLES COVERED WITH A GEM-BISPHOSPHONATE STABILIZING LAYER COUPLED TO HYDROPHILIC BIODISTRIBUTION LIGANDS | GMNN, PHOSPHO1, GEMIN4 | CRBN 972/4885MEN1 205/4885KMT2A 4019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.